Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | HCK | P08631 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394140 | 0.89 | PIK3CD (0.45) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1057530 | 0.86 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL30066410 | 0.86 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL5339277 | 0.85 | PIK3CD (0.45) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL13262833 | 0.83 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1468880 | 0.83 | PIK3CD (0.42) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3387968 | 0.83 | CA12 (0.43) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1468882 | 0.83 | PIK3CD (0.42) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1881676 | 0.83 | PIK3CD (0.42) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1273077 | 0.82 | HTR6 (0.49) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| CN-104136431-A | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO | 2014-11-05 | — | — | CN | disclosed |
| EP-2794597-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | PIK3CD 4229/4885ABL1 1164/4885EGFR 1240/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | PIK3CD 4229/4885ABL1 1164/4885EGFR 1240/4885 |
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | PIK3CD 527/4885ABL1 106/4885EGFR 1082/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | PIK3CD 3594/4885ABL1 1519/4885EGFR 2889/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | PIK3CD 510/4885ABL1 75/4885EGFR 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.